• Nanion Technologies: イオンチャネル研究のスマートツール

    Nanion Technologies: イオンチャネル研究のスマートツール

  • SyncroPatch 384i: HTS Automated Patch Clamp

    SyncroPatch 384i: HTS Automated Patch Clamp

  • SURFE²R 96SE: ラベルフリーのトランスポーターHTS

    SURFE²R 96SE: ラベルフリーのトランスポーターHTS

  • Dynamic Clamp: Patchliner

    Dynamic Clamp: Patchliner

  • 脂質二分子膜実験: Orbitシリーズ

    脂質二分子膜実験: Orbitシリーズ

  • CardioExcyte 96 SOL: 心筋の光ペーシング

    CardioExcyte 96 SOL: 心筋の光ペーシング

Our Product Portfolio

SyncroPatch 384i

SyncroPatch 384i

Patchliner

Patchliner

Port-a-Patch

Port-a-Patch

Port-a-Patch mini

Port-a-Patch mini

CardioExcyte 96

CardioExcyte 96

FLEXcyte 96

FLEXcyte 96

SURFE²R 96SE

SURFE²R 96SE

SURFE²R N1

SURFE²R N1

Orbit 16

Orbit 16

Orbit Mini

Orbit Mini

Vesicle Prep Pro

Vesicle Prep Pro

B'SYS - CRO

Our collaboration partner B'SYS is offering Services on Nanion's Instruments

Logo BSys

B'SYS GmbH is a leading European Ion Channel CRO and has a comprehensive library of validated human ion channel expressing cell lines. With its team of experienced electrophysiologists and facilities in Switzerland, B’SYS serves the needs of pharmaceutical and biotech customers worldwide. Since 2003 B’SYS successfully works together with suppliers of automated patch clamp- and MEA recording platforms and customers to speed the drug-development process and thus, to save time and money on the way to better and safer drugs.


B’SYS services include:


Ion channel testing and service offering:

BSYS validates the function, and pharmacology of each cell line using conventional and automated methods, and arranges them into ion channel panels. B’SYS uses its catalog for primary and secondary screening of drug targets during drug discovery and development. In addition, B’SYS licenses ion channel cell lines and pertaining reagents to assist customers with in discovery and profiling. With its highly qualified and flexible team B’SYS operates from laboratories located in Witterswil, Switzerland.

B’SYS is an independent and privately owned company and is free from conflicts of interest regarding public funding.


Statement about the CardioExcyte 96 from Dr. Daniel Konrad, CEO of B'SYS:

"Impedance and field potential data of beating cardiomyocytes is getting increasingly important to obtain a comprehensive view of the cardiac liability of test compounds. To answer these questions for our clients, B’SYS successfully implemented the CardioExcyte 96 system and provides related validated services to its customers, mostly using ipS derived cardiomyocytes. B’SYS’ scientists are pleased with the CardioExcyte’s ease of operation and data acquisition. The powerful software allows for applying meaningful data analysis and time saving export of data as needed for our daily customer reports."

Back

Nanion コーポレートブログ

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.